Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 4Multiple Myeloma 3Lymphoma, Non-Hodgkin 3Lymphoma, Follicular 3Lymphoma 3Endometrial Neoplasms 3Ovarian Neoplasms 2Leukemia, Lymphocytic, Chronic, B-Cell 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Rectal Neoplasms 1Prostatic Neoplasms 1Platinum-Refractory Fallopian Tube Carcinoma 1Pancreatic Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Melanoma 1Malignant Solid Neoplasm 1Lymphoma, Mantle-Cell 1Lymphoma, B-Cell, Marginal Zone 1Lung Neoplasms 1Leukemia, Lymphoid 1Hematologic Neoplasms 1Glioma 1Gallbladder Neoplasms 1Estrogen Receptor Positive 1Esophageal Neoplasms 1

Interventions

Gemcitabine 53Bevacizumab 52Cyclophosphamide 49Docetaxel 42Carboplatin 40pembrolizumab 37Paclitaxel 36Fluorouracil 36Cisplatin 35Radiotherapy 31Oxaliplatin 31Capecitabine 29Irinotecan 28Dexamethasone 27Leucovorin 25Cetuximab 25Nivolumab 24Doxorubicin 22Drug Therapy 21Erlotinib Hydrochloride 20Pemetrexed 19durvalumab 18trametinib 17fludarabine 16atezolizumab 16Trastuzumab 16Sunitinib 16Rituximab 16Prednisone 16Sorafenib 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Neoplasms × copanlisib × Clear all
NCT03474744 2026-05-06

Copanlisib and Rituximab in Marginal Zone Lymphoma Patients

University of Ulm

Phase 2 Active not recruiting
36 enrolled
Lymphoid

Neoplasms, Lymphoma, B-Cell, Marginal Zone

Data powered by HemOnc (CC BY 4.0) Colophon âš¡